Moe Alsumidaie


Ketamine-Like Compound Offers New Hope as a Potential Antidepressant and Non-opioid Painkiller

Shawn Singh, CEO of VistaGen Therapeutics’, discusses the company’s pipeline of new generation drug candidates for depression, neuropathic pain, Parkinson’s dyskinesia, social anxiety disorder, and suicidal ideation with potential for convenient, at-home use, rapid-onset therapeutic benefits, and exceptional safety.